PTC Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · New Jersey, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
500 Warren Corporate Center Dr, Warren, ...Phone Number
(908) 222-7000Website
www.ptcbio.comRevenue
$1 BillionStock Symbol
PTCTIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
2
1
2
1
1
About PTC Therapeutics
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The companys lead product is Translarna (ataluren), for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. The company is headquartered in South Plainfield, New Jersey.Explore more
PTC Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is PTC Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at PTC Therapeutics
Check if PTC Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if PTC Therapeutics is spiking on competitors!
Earning: See what the market has to say on PTC Therapeutics recently announced quarterly report
Product Launch: Get notified when PTC Therapeutics launches new products
PTC Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if PTC Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once PTC Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at PTC Therapeutics
Find 3 more new buyers
Compare Similar Companies to PTC Therapeutics
Compare insights from companies similar to PTC Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
PTC Therapeutics
$1B
501-1,000
Public
$2.5B
1998
DM
Daphny MassingaleSenior Director, Chief of Staff and Commercial Operations- North America
$3.2B
1K - 5K
Public
$54M
1996
ML
Marc LorberSenior Vice President and Chief Medical Officer, Lung Biotechnology, PBC
Company Profile Activity
Activity Insights
PTC Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
PTC Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about PTC Therapeutics.
PTC Therapeutics financials insights
Gather financial insights about PTC Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2012
Series G
$30M
Grant
$1M
2013
Series H
$60M
Stock Offering
$144.4M
2014
Stock Offering
$118M
Stock Offering
$117.5M
2015
Debt
$145.2M
2018
Stock Offering
$117.9M
2019
Multiple Rounds
$611.6M
2022
Debt
$1B
PTC Therapeutics Tech Stack
A closer look at the technologies used by PTC Therapeutics
See more technologies
Most Recent Scoops
Person-Based
Matthew Klein will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026.
Events
Person-Based
Clinical Operations
Person-Based
Stake & Stock Ownership, Finance
Open Position
Person-Based
Events
PTC Therapeutics News & Media
PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile
– 17 abstracts and presentations planned at SSIEM Symposium – – Real-world evidence demonstrates significant diet liberalization achieved with Sephience while maintaining target blood Phe levels – – Continued evidence of meaningful benefit across all patient subgroups – WARREN, N.J., Aug....PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program
– Planned acquisition leverages existing regulatory and commercial infrastructure and leadership's experience in Fabry therapy commercialization – – ST-920 is a one-time administered AAV gene therapy for the enzyme deficient in Fabry disease with demonstrated long-term clinical benefits...PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
– Robust Q2 performance with total revenue of $361 million, including $239 million of product revenue – – Full-year 2026 expected total revenue increased to $1.18 to $1.28 billion, with full-year product revenue guidance raised to $850 to $950 million – – Sephience™ (sepiapterin) Q2 2026...PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026
WARREN, N.J., July 16, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its second quarter 2026 financial results and provide an update on the company's business and outlook on Thursday, July 30,...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding PTC Therapeutics
Sign Up For FreeTo access detailed company insights
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The companys lead product is Translarna (ataluren), for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patien... Read More
